Rosuvastatin pretreatment does not attenuate microalbuminuria after coronary artery bypass grafting

Basit Öğe Kaydı
dc.authoriddisli, olcay murat/0000-0002-9699-4817
dc.authoridTaskapan, Mehmet Cagatay/0000-0002-5273-4909
dc.authoridErdil, Nevzat/0000-0002-8275-840X
dc.authoridAkpinar, Mehmet Besir/0000-0002-4220-8390;
dc.authorwosiddisli, olcay murat/ABI-3289-2020
dc.authorwosidUYAR, IHSAN SAMI/AAC-9760-2020
dc.authorwosidabacilar, ahmet feyzi/HOH-1500-2023
dc.authorwosidTaskapan, Mehmet Cagatay/ABI-7747-2020
dc.authorwosidErdil, Nevzat/K-8079-2019
dc.authorwosidAkpinar, Mehmet Besir/GLS-3733-2022
dc.authorwosidBattaloglu, Bektas/ABI-6211-2020
dc.contributor.authorSecici, Serkan
dc.contributor.authorBattaloglu, Bektas
dc.contributor.authorUyar, Ihsan Sami
dc.contributor.authorAkpinar, Mehmet Besir
dc.contributor.authorAbacilar, Ahmet Feyzi
dc.contributor.authorDisli, Olcay Murat
dc.contributor.authorErdil, Nevzat
dc.date.accessioned2024-08-04T20:39:51Z
dc.date.available2024-08-04T20:39:51Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractBackground: This study aims to evaluate whether rosuvastatin attenuates microalbuminuria following coronary artery bypass grafting (CABG) with a cardiopulmonary bypass (CPB). Methods: This prospective study was performed in 40 patients (37 males, 3 females; mean age 59.0 +/- 10.1 years; range 48 to 78 years) who were scheduled for isolated CABG. The patients were divided into two groups including control group (n=20) and rosuvastatin group (n=20) which received rosuvastatin 20 mg/day seven day (20 mg/day) before elective CABG. Microalbuminuria was measured after the insertion of the urinary catheter, before CPB, after the termination of CPB, and at the sixth and 24th hours in the intensive care unit using a spot urine sample. Serum C-reactive protein was measured before the induction of anesthesia and at the sixth and 24th hours in the intensive care unit using blood samples. Results: The demographic data and preoperative characteristics of the patients were similar. There were no significant differences in the CPB, cross-clamp and surgery time, inotropic support, extubation times, and time to discharge from hospital between the two groups. The urinary albumin/creatinine ratio increased in both groups, compared to the baseline measurement and reached a maximum level at the end of CPB (p<0.05). Albumin/creatinine ratio measured at the sixth hour in the intensive care unit was significantly higher in the rosuvastatin group (0.69 vs. 2.10, p=0.002). Serum C-reactive protein increased at 24 hour postoperatively in both groups. Conclusion: Rosuvastatin pretreatment does not attenuate microalbuminuria and the inflammatory response after CABG surgery.en_US
dc.identifier.doi10.5606/tgkdc.dergisi.2014.8991
dc.identifier.endpage501en_US
dc.identifier.issn1301-5680
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84907249400en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage496en_US
dc.identifier.urihttps://doi.org/10.5606/tgkdc.dergisi.2014.8991
dc.identifier.urihttps://hdl.handle.net/11616/96555
dc.identifier.volume22en_US
dc.identifier.wosWOS:000339225600003en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherBaycinar Medical Publ-Baycinar Tibbi Yayinciliken_US
dc.relation.ispartofTurk Gogus Kalp Damar Cerrahisi Dergisi-Turkish Journal of Thoracic and Cardiovascular Surgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCoronary artery bypass grafting surgeryen_US
dc.subjectmicroalbuminuriaen_US
dc.subjectrosuvastatinen_US
dc.subjectsystemic inflammatory responseen_US
dc.titleRosuvastatin pretreatment does not attenuate microalbuminuria after coronary artery bypass graftingen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu